FDA Licensed Ebola Virus Therapeutics

The Biomedical Advanced Research and Development Authority (BARDA) is seeking information from current and potential biopharmaceutical partners regarding FDA-licensed therapeutics for the treatment of Ebola virus. Respondents are asked to provide information about their existing FDA-licensed therapeutics, including product type, mechanism of action, patient dosing regimen, and regulatory and licensure information. The information collected will serve as continued market research for possible future acquisitions and programs. Some key points to consider: • The therapeutics must be licensed by the FDA for the treatment of individuals infected with Ebola virus. • Respondents must provide an overview of their existing FDA-licensed therapeutic, including product type and mechanism of action. • Respondents must also provide regulatory and licensure information, including FDA licensure date and approved indications. • The submission should be limited to five pages or less and must be submitted electronically to the BDR Portal.